Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $6.60.

A number of equities analysts recently issued reports on CNTX shares. Piper Sandler upped their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Wall Street Zen cut shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Guggenheim reiterated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research report on Tuesday, March 24th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday, March 24th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd.

Context Therapeutics Stock Down 4.6%

Shares of Context Therapeutics stock opened at $1.45 on Thursday. The company has a market capitalization of $133.23 million, a price-to-earnings ratio of -3.45 and a beta of 1.61. Context Therapeutics has a 12-month low of $0.56 and a 12-month high of $3.62. The firm’s 50-day moving average price is $2.39 and its two-hundred day moving average price is $2.09.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, sell-side analysts expect that Context Therapeutics will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Context Therapeutics in the 4th quarter valued at approximately $43,000. Sanctuary Advisors LLC bought a new position in Context Therapeutics in the 1st quarter valued at approximately $51,000. Quadrature Capital Ltd bought a new position in Context Therapeutics in the 4th quarter valued at approximately $68,000. Citadel Advisors LLC bought a new position in Context Therapeutics in the 3rd quarter valued at approximately $100,000. Finally, XTX Topco Ltd raised its holdings in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.